Paraoxonase and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 4, 2001, Pages 473-480

  Durrington, P N ^a   Mackness, B ^a   Mackness, M I ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

High density lipoproteins; Lipid peroxidation; Paraoxonase

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; ISOENZYME; LOW DENSITY LIPOPROTEIN; OXIDIZING AGENT; VITAMIN;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; DIABETES MELLITUS; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TRANSGENIC MOUSE;

EID: 0035048212     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.4.473     Document Type: Short Survey

References (121)

1. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family
2. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins
3. Paraoxonase genes and disease
4. Structural organisation of the human PON1 gene
5. Cloning and characterisation of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human
6. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in non-insulin-dependent diabetes mellitus
7. Low paraoxonase activity in type II diabetes complicated by retinopathy
8. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation
9. Reverse cholesterol transport and atherosclerosis
10. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit
11. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits
12. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits
13. Lack of apo A-1 is not associated with increased susceptibility to atherosclerosis in mice
14. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
15. The gene encoding ATP-binding cassette transport 1 is mutated in Tangier disease
16. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
17. Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred
18. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
19. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B
20. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk
21. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins
22. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridaemic men: Genetic and pharmacological evidence
23. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
24. Cholesteryl ester transfer protein and atherosclerosis
25. Role of oxidized low density lipoprotein in atherogenesis
26. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture
27. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
28. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
29. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation
30. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein
31. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidised low-density lipoprotein
32. Paraoxonase inhibits high-density lipoprotein and preserves its functions
33. Evidence for a paraoxonase independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein
34. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation
35. Recognition of oxidised low density lipoprotein by the scavenger receptor of macrophages results from derivatisation of apolipoprotein B by products of fatty acid peroxidation
36. HDL prevents the formation of aldehyde adducts of apolipoprotein B during the oxidation of LDL
37. Vitamin E supplementation and cardiovascular events in high-risk patients
38. Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity
39. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
40. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective active of human paraoxonase alloenzymes Q and R
41. High-density lipoprotein associated enzymes and the prevention of low-density lipoprotein oxidation
42. Lack of protection against oxidative modification of LDL by avian HDL
43. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
44. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon
45. Hydrolysis of platelet-activating factor by human serum paraoxonase
46. "A"-esterase activity in the lipoprotein fraction of sheep serum
47. Apolipoprotein J is associated with paraoxonase in human plasma
48. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-85: Identity of K-85 with paraoxonase
49. Apolipoprotein J: A membrane policeman?
50. Presence of paraoxonase in human interstitial fluid
51. Certain clinical features of sudden obstruction of the coronary arteries
52. Structural and functional diversity of paraoxonases
53. Calcium-dependent human serum homocysteine thiolactone hydrolase
54. Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase
55. Human serum paraoxonase (PON1) isoenzymes Q and R hydrolyse lactones and cyclic carbonate esters
56. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease
57. Low A-esterase activity in serum of patients with fish-eye disease
58. Absence of A-esterase activity in the serum of a patient with Tangier disease
59. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
60. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes
61. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
62. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation
63. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
64. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat
65. Daily moderate alcohol consumption increases serum paraoxonase activity: A diet-controlled, randomised intervention study in middle-aged men
66. Low paraoxonase in Persian Gulf War veterans self-reporting Gulf War syndrome
67. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans
68. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response
69. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response
70. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism
71. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
72. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
73. 192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus
74. A 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
75. Paraoxonase 192 Glu/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes
76. Paraoxonase gene polymorphism and coronary artery disease in Indian subjects
77. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases
78. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
79. The Gln-Arg polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
80. Risk of myocardial infarction with Gln/Arg 192 polymorphisms in the human paraoxonase gene and diabetes mellitus
81. Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages and association with coronary artery disease
82. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
83. The Gln-Arg 192 polymorphism of the human paraoxonase gene is not associated with coronary artery disease in Italian patients
84. The paraoxonase Gln-Arg polymorphism in subjects with ischaemic heart disease
85. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
86. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan
87. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
88. Differential effects of smoking on myocardial infraction risk according to the Gln/Arg 192 variants of the human paraoxonase gene
89. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase gene: The Regicor study
90. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease
91. Polymorphism in high density lipoprotein gene and risk of acute myocardial infarction in men: Prospective nested case-control study
92. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis: Results of Austrian Stroke Prevention Study
93. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: Three-year follow-up of the Austrian Stroke Prevention Study
94. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme
95. The codon 55 polymorphism of the paraoxonase 1 gene is not associated with risk of coronary heart disease in Asian Indians and Chinese
96. Promoter polymorphisms of human paraoxonase PON1 gene and serum activities and concentrations
97. Distribution of paraoxon hydrolysing activity in the serum of patients after myocardial infarction
98. Serum paraoxonase after myocardial infarction
99. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
100. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
101. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
102. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
103. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure
104. The serum paraoxonase activity in patients with chronic renal failure and hyperlipedemia
105. Decrease of serum paraoxonase activity in chronic renal failure
106. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat
107. Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein AI in the human artery wall with progression of atherosclerosis
108. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxide-like activities
109. Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidants against lipoprotein oxidation
110. Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia
111. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
112. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinaemia treated with ciprofibrate
113. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolaemic patients
114. Reduced progression of atherosclerosis in apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation
115. Human serum paraoxonase/arylesterase
116. Brain abnormalities in Gulf War syndrome: Evaluation with 39 NMR spectroscopy
117. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM
118. Gln→Arg 191 polymorphism of paraoxonase and Parkinson's disease
119. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease